Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 6 | 2022 | 548 | 0.990 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 68 | 0.660 |
Why?
|
| Immunologic Factors | 1 | 2020 | 184 | 0.610 |
Why?
|
| Immunotherapy | 2 | 2020 | 746 | 0.550 |
Why?
|
| Myofibromatosis | 1 | 2025 | 10 | 0.230 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 56 | 0.210 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 46 | 0.180 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 12 | 0.180 |
Why?
|
| Peritonitis | 1 | 2021 | 76 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 50 | 0.170 |
Why?
|
| Granuloma, Giant Cell | 1 | 2020 | 12 | 0.170 |
Why?
|
| Denosumab | 1 | 2020 | 14 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 57 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 94 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 25 | 0.170 |
Why?
|
| Bone Density Conservation Agents | 1 | 2020 | 56 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 149 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 95 | 0.160 |
Why?
|
| Neutropenia | 1 | 2020 | 205 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 189 | 0.150 |
Why?
|
| Pneumonia | 1 | 2022 | 336 | 0.150 |
Why?
|
| Child | 11 | 2022 | 25777 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2019 | 295 | 0.140 |
Why?
|
| Neuroimaging | 1 | 2020 | 374 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2020 | 324 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2021 | 607 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 529 | 0.120 |
Why?
|
| Exanthema | 1 | 2017 | 74 | 0.120 |
Why?
|
| Pyridazines | 1 | 2016 | 54 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 729 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 218 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 258 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 816 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 226 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 402 | 0.110 |
Why?
|
| Skin | 1 | 2017 | 540 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1190 | 0.100 |
Why?
|
| Cell Movement | 1 | 2016 | 894 | 0.100 |
Why?
|
| Humans | 17 | 2025 | 132278 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 607 | 0.090 |
Why?
|
| Prognosis | 4 | 2022 | 5006 | 0.090 |
Why?
|
| Infant | 3 | 2020 | 13177 | 0.080 |
Why?
|
| Neoplasms | 1 | 2022 | 2947 | 0.070 |
Why?
|
| Female | 7 | 2022 | 70774 | 0.070 |
Why?
|
| Adolescent | 5 | 2022 | 20510 | 0.060 |
Why?
|
| Vinblastine | 1 | 2025 | 58 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2025 | 8558 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 2186 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1963 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17345 | 0.050 |
Why?
|
| Methotrexate | 1 | 2025 | 351 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 54 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 62 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 43 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 55 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 285 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 74 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 134 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 106 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 151 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 224 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5399 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 198 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 104 | 0.040 |
Why?
|
| Male | 6 | 2025 | 64994 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2020 | 61 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 6534 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2020 | 14831 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 956 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 368 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2025 | 847 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 1176 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 210 | 0.040 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 675 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 634 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1452 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 758 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1347 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1067 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2022 | 13002 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 2067 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 1002 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1297 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 1409 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2166 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 31585 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1303 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1907 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2515 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3851 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3700 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 28848 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 18622 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 35136 | 0.010 |
Why?
|